Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global pharmaceutical company focused on making medicines more accessible, with a portfolio spanning generic, complex generic, branded, and innovative medicines. With a market cap of $10.4 billion, Viatris serves patients across 165+ countries and territories and covers more than 10 major therapeutic areas, including cardiovascular disease, oncology, diabetes, respiratory health, and infectious diseases.
Companies worth $10 billion or more are generally described as "large-cap stocks." Viatris fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the specialty & generic drug manufacturing industry.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Viatris has more than 1,400 approved molecules and sells more than 80 billion doses annually. The company is also investing in higher-value products, including complex generics, value-added medicines, and innovative therapies, to move beyond its traditional generic-drug base.
Viatris has kept its upward trajectory intact, falling just 6.9% from the 52-week high of $18.39 on Aug. 6. Over the past three months, VTRS stock has surged 8.7%, significantly outperforming the S&P 500 Index’s ($SPX) 4.7% return during the same time frame.
www.barchart.comViatris has delivered strong absolute gains over the long term, with shares climbing 37.5% year to date and 78.3% over the past 52 weeks, outpacing the S&P 500, which climbed 12.6% in 2026 and 15.8% over the past year.
VTRS’ technical picture remains firmly positive, with the stock holding above its 200-day moving average throughout the past year and staying above its 50-day average since mid-April, signaling sustained upward momentum.
www.barchart.comVTRS’ solid price performance over the past year is driven by improving business momentum, strong cash generation, and progress in its higher-value product portfolio. The company’s focus on complex generics, innovative medicines, and cost efficiencies has helped strengthen its financial profile, while its sizable global portfolio provides relatively diversified revenue streams.
Viatris shares popped 2.2% on Sept. 16 after the company announced that Japan’s Ministry of Health, Labour and Welfare approved WAKIX (pitolisant) for excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy. The approval marks WAKIX as the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these conditions, strengthening Viatris’ innovative medicines portfolio and expanding its presence in the Japanese market.
Within the pharma industry, Viatris has delivered a notably stronger performance than its key rival Sanofi (SNY), with Sanofi shares down 14% in 2026 and 11.1% over the past 52 weeks.
Among the 11 analysts covering the VTRS stock, the consensus rating is a “Moderate Buy.” Its mean price target of $19 suggests an 11% upside potential from current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Get Paid to Wait: Buy HOOD at a Discount or Earn Options Income Peloton’s New Folding Treadmill Might Not Be a Magical Fix for PTON Stock Nasdaq Futures Plunge as Rising Bond Yields Deepen Chip Selloff, Trump-Xi Summit in Focus How to Play AAPL Stock as New Fitness+ Layoffs Hit Apple